Cyclin I inhibitors belong to a class of small molecules that play a crucial role in regulating the cell cycle, particularly the G1 phase, where cells prepare for DNA replication and division. To understand cyclin I inhibitors, it is essential to first grasp the function of cyclin I itself. Cyclin I is a protein that, in conjunction with cyclin-dependent kinases (CDKs), modulates the progression of the cell cycle by regulating the transition from the G1 phase to the S phase. During the G1 phase, cyclin I binds to CDKs, forming an active complex that phosphorylates key substrates, allowing the cell to progress through checkpoints and initiate DNA synthesis. Cyclin I inhibitors, as their name suggests, are compounds designed to impede this interaction between cyclin I and CDKs, ultimately preventing cell cycle progression beyond the G1 phase.
These inhibitors typically act by binding to either cyclin I or CDKs, inhibiting their interaction and thereby preventing the phosphorylation of target proteins necessary for the cell to proceed through the cell cycle. By interfering with this essential step in cell division, cyclin I inhibitors have garnered significant interest in the realm of cell biology. Understanding the mechanisms and potential applications of these inhibitors can provide valuable insights into the regulation of cell growth and division, potentially leading to novel strategies for controlling cell proliferation in various contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Inhibits CDK4/6, potentially reducing cyclin I-associated kinase activity by limiting the activity of these related CDKs. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Inhibits multiple CDKs, could decrease cyclin I activity by altering CDK-cyclin complexes. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Targets CDKs, may reduce activity of CDK-cyclin I complexes by inhibiting their kinase activity. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Broad CDK inhibitor, could indirectly reduce cyclin I function by inhibiting CDKs that partner with cyclin I. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Inhibits CDK1, 2, and 5, could impact cyclin I activity by interfering with its associated CDKs. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Similar to Palbociclib, inhibits CDK4/6 and could affect cyclin I activity through CDK-cyclin regulation. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
Inhibits CDK1, 2, and 9, may influence cyclin I activity by altering CDK-cyclin interactions and function. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
Targets CDK2, 7, and 9, could impact cyclin I by modulating its associated CDKs' activities. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
Inhibits multiple CDKs, might alter cyclin I function through broad CDK inhibition. | ||||||
PHA-793887 | 718630-59-2 | sc-364580 sc-364580A | 5 mg 10 mg | $189.00 $432.00 | ||
Inhibits CDKs, could indirectly affect cyclin I by altering the kinase activity of its related CDKs. | ||||||